Page 32 - MemoriaER-Eng

HORIZONTAL PROGRAMMES

External Research of excellence requires top-level economic, material and human resources to
develop the activities and comply with objectives. Drawing in competitive and non-com-
Projects
petitive resources is fundamental for developing far-reaching projects and actions in RD.

In 2013, the CIBERER Management Office and the groups involved in the different ac-
tions continued working in that sense. The main actions in 2013 can be accounted for as:

Aids granted in 2013

The following table shows the grants and aids that were given in 2013 to competitive
CIBERER projects or actions either by public institutions or private institutions. The

type of project, the name of the principal investigator, the title or reason for the action

and the entity granting the aid are provided.

PROJECTS GRANTED IN 2013 IN COMPETITIVE CALLS FOR PROPOSALS

Project PI/ Funding
Group
Title
Work Group
Agency-Programme

International Scope
CIBERER éEuropean Network and ò
ó
(U746, Dr. Couce
Registry for Homocystinurias DG SANCO–Project
U720, U737, and Methylation Defects
U703)
(E-HOD).

CLC chloride channels
and Megalencephalic
CIBERER
U750
Dr. Estvez
leukoencephalopathy: CIBERER-E-RARE 2
molecular mechanisms and
therapeutics.

CIBERER
Dr. Bernal
THYRONERVE
CIBERER-E-RARE 2
U708

National Scope, Public Entity calling for Proposals

Study of the pathways
involved in the autism
CIBERER Dr. Cusc
spectrum: Functional ISCIII – FIS Health
U735
Research Projects
consequences of genetic and
epigenetic variants

Advancements in
McArdle’s disease. New
CIBERER therapeutic approaches and ISCIII – FIS Health
Dr. Pins
U701
development of a new, non- Research Projects
invasive diagnostic method
in patients.
13
Private Entity Calling for Proposals
20
T
Cellular and molecular R
characterization of the PO
E
CIBERER relationship between L R
Dr. Pujol
oxidative stress
Mehuer Foundation
A
U759
and inflammation in NU
N
adrenoleukodystrophy: A
therapeutic implications
/
ER
Preclinical study of the ER
effectiveness of TRIAC, a B
CIBERER Dr. Morte
thyroid hormone analogue, Mehuer Foundation
CI
U708
in the treatment of Allan-
Herndon-Dudley Syndrome.
32